-
AmVision Biotech Secures Nearly $14.34M in Series A+ for Ophthalmology Innovations
•
AmVision Biotech, a leading ophthalmology device platform company based in Guangzhou, has reportedly secured close to RMB 100 million (USD 14.34 million) in a Series A+ financing round. The round was led by Green Pine Capital Partners, with participation from ZDVC and existing investor HM Capital, among others. This significant…
-
JW Therapeutics Launches Carteyva Clinical Study for High-Risk Lymphoma
•
China-based JW Therapeutics (HKG: 2126) has announced the initiation of a clinical study for its Carteyva (relmacabtagene autoleucel injection) in the treatment of first-line high-risk large B-cell lymphoma. A significant milestone was reached with the completion of reinfusion therapy for the first patient. Previous Study Outcomes and Current Trial DesignThe…
-
Chongqing Evaheart Secures Near $100M in Series A for Heart Failure Platform
•
Chongqing Evaheart Medical Device Co., Ltd has reportedly secured close to USD 100 million in a Series A financing round. The round was led by Sinovac, with significant contributions from Taiping (Shenzhen) Healthcare Industry Private Equity Investment Fund and Vivo Capital. The funds raised will be directed towards the development…
-
Biocytogen and Janssen Sign Licensing Agreement for RenLite Platform
•
Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced the signing of a non-exclusive licensing agreement with Janssen Biotech Inc., a subsidiary of Johnson & Johnson (J&J, NYSE: JNJ). The agreement, facilitated by Johnson & Johnson Innovation LLC, grants Janssen and its affiliates a non-exclusive worldwide license to utilize Biocytogen’s…
-
Haihe Pharma’s Glumetinib Receives Conditional Approval for NSCLC Treatment
•
Shanghai Haihe Pharmaceutical Co., Ltd’s Category 1 product, glumetinib, has obtained conditional market approval from the National Medical Products Administration (NMPA). The small-molecule MET inhibitor is now approved for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with MET14 exon hopping. Development and Clinical FindingsGlumetinib, co-developed…
-
AmVision Biotech Secures RMB 100 Million in Series A+ Financing for Ophthalmology Innovation
•
AmVision Biotech, an ophthalmology device platform company based in Guangzhou, has reportedly raised close to RMB 100 million (USD 14.34 million) in a Series A+ financing round. The funding was led by Green Pine Capital Partners, with contributions from ZDVC and existing investor HM Capital, among others. This investment will…
-
JW Therapeutics Initiates Clinical Study for Carteyva in First-Line High-Risk Large B-Cell Lymphoma
•
China-based JW Therapeutics (HKG: 2126) has announced the initiation of a clinical study for its Carteyva (relmacabtagene autoleucel injection) in first-line high-risk large B-cell lymphoma. The first patient has already completed reinfusion therapy, marking a significant step in the study’s progress. Previous Study ResultsThe pivotal RELIANCE study previously demonstrated that…
-
Evaheart Med Raises USD 100 Million in Series A Funding Led by Sinovac
•
Chongqing Evaheart Medical Device Co., Ltd has reportedly raised close to USD 100 million in a Series A financing round led by Sinovac, with contributions from Taiping (Shenzhen) Healthcare Industry Private Equity Investment Fund and Vivo Capital. The proceeds will be used to develop and construct a comprehensive heart failure…
